Szpitale Tczewskie S.A.
- Address
- Ul. 30-Go Stycznia 57/58, 83-110 Tczew, Poland
Szpitale Tczewskie S.A. - Renal Disease Research Center
Szpitale Tczewskie S.A. is a specialized clinical research institution with extensive expertise in chronic kidney disease (CKD) and related cardiovascular complications. The center focuses on advancing therapeutic interventions for patients with progressive renal dysfunction, conducting pivotal trials that evaluate novel pharmaceutical approaches to slow disease progression and improve clinical outcomes.
- Chronic kidney disease progression and glomerular filtration rate preservation studies
- Hypertension management in patients with renal impairment
- End-stage kidney disease (ESKD) and cardiovascular risk reduction in dialysis populations
- Novel therapeutic combinations for renal protection, including SGLT2 inhibitors and aldosterone synthase inhibitors
The research center demonstrates particular strength in evaluating combination therapies for kidney protection, including studies with baxdrostat, dapagliflozin, empagliflozin, and vicadrostat. Their clinical trial portfolio encompasses dose-finding studies, comparative effectiveness trials, and cardiovascular outcome investigations in both early-stage CKD and end-stage kidney disease requiring dialysis. The center's research also addresses the critical intersection of chronic kidney disease with comorbid conditions such as type 2 diabetes and obesity, reflecting a comprehensive approach to managing complex renal patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpitale Tczewskie S.A.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2024-06-05 | 2025-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.